Toni Choueiri, MD:I think this is going to be a very important question. Nivolumab/ipilimumab hands-down beat the TKI sunitinib with an overall survival benefit. But there are many considerations. First and foremost are the toxicities and how practitioners are going to be familiar with managing immune-related adverse events. Second, the regimen has shown the activity mostly in intermediate and poor risk. Actually, if you look at the small group of patients with good-risk disease, responses and progression-free survival seem to favor sunitinib. Third, and most importantsomething we tend to forget about—is that immuno-oncology drugs now are given intravenously, whereas the TKIs are oral. So, there is a patient preference here between visiting the hospital and not visiting the hospital as frequently for the infusion.
So, it’s actually an evolving story, too. What I think is going to happen, rather than a TKI versus an I-O, is that there will be, in the next few years, several combination TKIs plus I-Os and that we need to figure out how to use them. Because, fortunately or not fortunately, all these combinations from phase III well-powered trials were compared against sunitinib and are not compared against each other. So, I think this is, again, an evolving story, and, hopefully, I’ll be here in the next few years to discuss these results.
The combination of bevacizumab/interferon showed activity in the frontline setting some time ago versus interferon, which we don’t use now. That combination doesn’t have any advantage currently over what we use in frontline studies. And we do not actually use it much.
Now, temsirolimus is a drug that showed activity against cytokines in patients with poor-risk renal cell cancer. I think the schedule of temsirolimus intravenous weekly and the fact that, overall in an indirect comparison, mTOR inhibitors usually have not fared as well as VEGF TKIs dampen our enthusiasm for using temsirolimus.
Transcript edited for clarity.
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Deciding Factors for Front-Line Therapy in Metastatic RCC
April 17th 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
Read More